Hay recursos disponibles en español. Explorar los recursos aquí »
For US Residents Only
Visit Health Care Professional Website
Patient Information (English |  Español)
  Indication
Important Safety Information
Prescribing Information
For people with 
Alagille syndrome...

BATTLE 
BILE ACID 
BUILDUP*

Take down 
cholestatic pruritus.

LIVMARLI is an FDA-approved medicine for cholestatic pruritus (itch) in patients with Alagille syndrome who 
are 3 months of age and older.

LIVMARLI HAS HELPED 600+ PATIENTS 
BATTLE BILE ACID BUILDUP†
Watch Videos

*LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor that interrupts bile acids from going back into the liver. In doing so, LIVMARLI lowers the amount of bile acids in the body because more bile acids are removed in feces. The way LIVMARLI improves cholestatic pruritus is not completely known.

More than 80% of patients experienced less itchiness than they felt at the start with LIVMARLI, with improvements seen as early as the very first assessment‡ and continued through the first year.

For patients who experienced a significant improvement in their itch—that is, more than a 1-point reduction in ItchRO[Obs])§— 93% were alive and did not have a liver transplant 6 years after starting LIVMARLI.

Backed by more than 5 years of data,|| LIVMARLI has a well-known safety record in patients with the itch in Alagille syndrome.

Over the last 6+ years, LIVMARLI has been used by 600+ patients to battle bile acid buildup.†

96% of patients are approved for LIVMARLI by their insurance and pay $10 or less per fill.#

Mirum Access Plus offers resources, education, and services to help you start and stay on LIVMARLI.

†Number includes all patients with cholestatic pruritus in Alagille syndrome treated with LIVMARLI in clinical studies, as well as those treated in the United States commercially and through the expanded access program.

‡Itch relief was first assessed at Week 3.

§Itch Reported Outcome for Observers (ItchRO[Obs]) is a tool designed for caregivers to measure itch severity over time.

||From extended observation of patients taking LIVMARLI after completing a placebo-controlled study.

Data from 1/1/2022 to 11/30/2022.

#Exceptions apply for some patients, including those with TRICARE insurance.

REAL PATIENT AND CAREGIVER STORIES

Hear from patients and families—and learn about the difference LIVMARLI has made in their lives.

Watch the Videos

How LIVMARLI May Help

Download the LIVMARLI Brochure Descargar el Folleto de LIVMARLI
Lightning bolt sticker

WELCOME TO THE LIVER LEAGUE INFORMATION BOOTH

Stay in the Know

To receive more information about LIVMARLI as it becomes available, please fill out the form below.

*Required.

By completing this form, you agree to our Terms of Use and Privacy Policy.

HOORAY!
Your sign-up was successful!

Be on the lookout for a welcome email from Mirum soon. Make sure to add livmarli-info@mirumpharma.com to your address book so that our emails go directly to your inbox.

YIKES!
We're having some connection trouble.

Refresh the page and try submitting your form again.

Note: This issue may occur if your email is already registered. Please check your inbox and spam folder to make sure you're receiving information. If the issue persists, please contact us.

OOPS!
Looks like this email is already registered.

Please check your inbox and spam folder to make sure you're receiving information.

Liver League kids

Indication

LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients with Alagille syndrome 3 months of age and older. It is not known if LIVMARLI is safe and effective in children under 3 months of age or in adults 65 years and older.

Important Safety Information

What are the possible side effects 
of LIVMARLI?

LIVMARLI can cause serious side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:

  • nausea or vomiting
  • skin or the white part of the eye turns yellow
  • dark or brown urine
  • pain on the right side of the stomach (abdomen)
  • loss of appetite

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your health care provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were gastrointestinal bleeding and bone fractures.

Tell your health care provider about all medicines that you take. LIVMARLI may affect the way some other medicines work, and some other medicines may affect the way LIVMARLI works. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.

LIVMARLI is taken by mouth, 1 time each day, 30 minutes before a meal in the morning. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Patient Information: English |  Español

expand btn collapse btn

Indication

LIVMARLI is a prescription medicine used to treat cholestatic pruritus (itch) in patients with Alagille syndrome 3 months of age and older. It is not known if LIVMARLI is safe and effective in children under 3 months of age or in adults 65 years and older.

Important Safety Information

What are the possible side effects 
of LIVMARLI?

LIVMARLI can cause serious side effects, including:

Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome but may worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your health care provider should do blood tests before starting and during treatment to check your liver function. Tell your health care provider right away if you get any signs or symptoms of liver problems, including:

  • nausea or vomiting
  • skin or the white part of the eye turns yellow
  • dark or brown urine
  • pain on the right side of the stomach (abdomen)
  • loss of appetite

Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your health care provider right away if you have any of these symptoms more often or more severely than normal for you.

A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamins A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your health care provider should do blood tests before starting and during treatment.

Other common side effects reported during treatment were gastrointestinal bleeding and bone fractures.

Tell your health care provider about all medicines that you take. LIVMARLI may affect the way some other medicines work, and some other medicines may affect the way LIVMARLI works. If you take a medicine that lowers cholesterol by binding bile acids, such as cholestyramine, colesevelam, or colestipol, take it at least 4 hours before or 4 hours after you take LIVMARLI.

LIVMARLI is taken by mouth, 1 time each day, 30 minutes before a meal in the morning. Be sure to use the provided oral dosing dispenser to accurately measure the dose of medicine.

These are not all of the possible side effects of LIVMARLI. Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see Patient Information: English |  Español